Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies

Adriana Bajetto¹ | Stefano Thellung¹ | Irene Dellacasagrande¹ | Aldo Pagano²,³ | Federica Barbieri¹ | Tullio Florio¹,³

¹Dipartimento di Medicina Interna, Università di Genova, Genova, Italy
²Dipartimento di Medicina Sperimentale, Università di Genova, Genova, Italy
³IRCCS Ospedale Policlinico San Martino, Genova, Italy

Correspondence
Tullio Florio, MD, PhD, and Federica Barbieri, PhD, Section of Pharmacology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 2, 16132 Genova, Italy. Email: tullio.florio@unige.it (T. F.) and Email: federica.barbieri@unige.it (F. B.)

Abstract
Mesenchymal stem cells (MSCs) can be isolated from bone marrow or other adult tissues (adipose tissue, dental pulp, amniotic fluid, and umbilical cord). In vitro, MSCs grow as adherent cells, display fibroblast-like morphology, and self-renew, undergoing specific mesodermal differentiation. High heterogeneity of MSCs from different origin, and differences in preparation techniques, make difficult to uniform their functional properties for therapeutic purposes. Immunomodulatory, migratory, and differentiation ability, fueled clinical MSC application in regenerative medicine, whereas beneficial effects are currently mainly ascribed to their secretome and extracellular vesicles. MSC translational potential in cancer therapy exploits putative anti-tumor activity and inherent tropism toward tumor sites to deliver cytotoxic drugs. However, controversial results emerged evaluating either the therapeutic potential or homing efficiency of MSCs, as both antitumor and protumor effects were reported. Glioblastoma (GBM) is the most malignant brain tumor and its development and aggressive nature is sustained by cancer stem cells (CSCs) and the identification of effective therapeutic is required. MSC dualistic action, tumor-promoting or tumor-targeting, is dependent on secreted factors and extracellular vesicles driving a complex cross talk between MSCs and GBM CSCs. Tumor-tropic ability of MSCs, besides providing an alternative therapeutic approach, could represent a tool to understand the biology of GBM CSCs and related paracrine mechanisms, underpinning MSC-GBM interactions. In this review, recent findings on the complex nature of MSCs will be highlighted, focusing on their elusive impact on GBM progression and aggressiveness by direct cell-cell interaction and via secretome, also facing the perspectives and challenges in treatment strategies.

Keywords
cancer stem cells, extracellular vesicles, glioblastoma, mesenchymal stem cells, secretoma

© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press

1310 | wileyonlinelibrary.com/journal/sct3

STEM CELLS Transi Med. 2020;9:1310–1330.
INTRODUCTION

1.1 Mesenchymal stem cells: Origin and isolation

Mesenchymal stem cells (MSCs) are adult multipotent stem cells that harbor, although rare, in the bone marrow (BM) and in almost all body tissues.\(^1\)\(^2\) The classical and widely used sources of human MSCs for clinical settings are the BM, the adipose tissue (AT), and the umbilical cord (UC),\(^5\) exhibiting peculiar in vivo biology and different native functions (see Table 1 for details), which represent a promising tool for cell therapy, tissue engineering, and regenerative medicine. More recently, Wharton’s jelly (WJ), amnion and corion,\(^5\) and umbilical cord blood (UCB)\(^6\) were proposed as alternative source of MSCs, although in the UCB they were identified at very low frequency as compared to other tissues.\(^7\) MSCs have been harvested also from endometrium, synovium,\(^8\) muscle,\(^9\) skin, placental,\(^10\) and dental pulp.\(^11\) Increasing evidence proposes the use of MSCs as promising therapeutic approach for the treatment of several diseases and applications in the fields of regenerative medicine, neuroscience, oncology, pharmacology, and bioengineering. Currently, more than 500 studies (recruiting, not yet recruiting, active not recruiting on May 2020; search terms: MSC and mesenchymal stromal cell) are registered for MSCs, according to https://ClinicalTrials.gov.

At present, the extension of the concept and term MSC, originally circumscribed to nonhematopoietic BM-derived cells, to cells derived from additional postnatal tissues, rises some concerns. In particular, the MSC concept was questioned as far as two main defining stem cell assumptions, self-renewal and multipotency, and concerning the experimental approaches used for isolation and characterization. Indeed, MSCs from different tissue sources comprise differences in cell populations, which display distinct characteristics, technical difficulties and advantages, and clinical translation potential.\(^1\)\(^2\)

### Significance statement

Mesenchymal stem cells (MSCs) attract interest for their unique potential properties, which make them a suitable resource for the treatment of several human disorders. As yet, MSC-based therapy has been applied to degenerative and inflammatory diseases, tissue repair, and to fight cancer. The present review focuses on recent findings from preclinical studies on MSCs in oncology as a source of soluble factors and extracellular vesicles (EVs), underscoring MSC interaction with glioblastoma (GBM) in in vivo and in vitro models. Importantly, because MSCs may promote or suppress tumor growth, they act as a double-edged sword in the GBM model, as in other tumor types. The review also addresses the evidence for challenges, risks, and further research investigations needed to carefully explore and defines the actual MSC nature, before their clinical translation as effective and safe tools for future anticancer approaches.

Furthermore, large-scale high quality ex vivo isolation of MSCs is hampered by the low prevalence in human tissues and suboptimal in vitro expansion protocols, which are unable to maintain MSC essential properties required for therapeutic applications.

MSCs in vitro expansion for therapeutic applications might impact proliferative rate, homing molecules, genetic stability, transcriptional processes, multipotency, transformation, and senescence of isolated MSCs,\(^1\)\(^2\)\(^3\)\(^4\) rising critical biosafety issues.\(^5\) In this context, the optimization of culture conditions (medium, serum, supplements, substrates) to preserve MSC phenotype, homogeneity, fate, and better mimic

### TABLE 1  In vivo and in vitro biological characteristics of MSCs most commonly used in clinical studies

| MSC source    | In vivo role                                           | Collection/isolation                        | In vitro biological features                                                                 |
|---------------|--------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------|
| Bone marrow   | Formation and maintenance of the hematopoietic stem cell niche | Invasive collection procedure/0.001%-0.01% of the total BM nucleated cells | Level of differentiation ability: High estrogentic and chondrogenic potential; Immunophenotype: Stro-1+, SSEA-4+, CD146+, CD106+, CD271+ |
| Adipose tissue| Localized within the stromal vascular fraction regulate local of angiogenesis and vessel remodeling | Ease of collection/high availability (~500-fold as compared to BM-MSC) | High adipogenic potential, endothelial cells; CD34+ (at least in early in vitro passages), CD10+, CD36+, CD49d, CD106+; Good proliferative capacity and high clonogenicity senescence |
| Umbilical cord| Maintenance of stromal tissue by differentiating into myofibroblasts to elaborate ECM | Non-invasive collection procedure/low frequency of MSC | High chondrogenic potential; Stro-1+, SSEA-4+, CD146+, CD271-; High proliferative capacity and clonogenicity (compared to BM and AT)/low senescence |
their natural microenvironment (ie, the niche) during expansion, should be integrated with processes allowing large-scale production of quality MSC, to be used in both preclinical and clinical studies.

Isolation and ex vivo expansion of MSCs are also crucial steps to ensure adequate material for potential clinical application. Commonly, MSC isolation exploits their plastic-adherence ability, which allows quite easy cell recovery and grow in a defined culture medium; however, this protocol implies low homogeneity of freshly-isolated cells, which increases during long-term expansion in vitro, necessarily combined with maintenance of differentiation ability, essential to make MSC reliable candidate for medical biotechnology.

Alternatively, the separation of MSCs could be performed by mechanical or enzymatic approaches although with higher impact on biological properties of the isolated cells.16 Therefore, standardized separation techniques, allowing MSC purity or optimal enrichment, could significantly improve the reliability of results from in vitro and in vivo experimental approaches as well as clinical trials.

1.2 Defining criteria: Properties and markers

The key step to verify MSC identity, following plastic adherence, is the assessment of cell immune phenotyping and multipotency.

Indeed, in the absence of unique and common markers, minimal criteria for MSC definition have been formulated by the International Society for Cellular Therapy (ISCT): (a) plastic adherence under the standard culture conditions; (b) positivity for CD73, CD90, and CD105 cell surface markers, coupled with the absence of the endothelial and hematopoietic stem cell proteins CD14, CD19, CD34, CD45, CD79α, and HLA-DR; (c) differentiation into osteoblasts, adipocytes, and chondrocytes in vitro.17 Although MSCs from different sources share the minimum standard criteria set by ISCT, many studies suggest that each tissue of origin has a different MSC content, and influences in vitro MSC features, such as the proliferative rate, the differentiation potential, and the marker expression profile (Table 1).18,19

On the contrary, the in vivo molecular signature of MSCs is still undefined and scantly investigated,20 as well as the exact matching between their in vitro and actual native behavior in vivo.21 In this context, CD271+/CD140a+ MSCs have been proposed to fulfill stringent stem cell criteria of self-renewal and multipotency, also in vivo.22

STRO-1 marker, not included in ISCT criteria, is used to immune-select fresh BM-MSCs, although it decreases during in vitro expansion of the culture23 and it is not univocally present in MSCs, but it is also expressed by endothelial cells.24 Also CD146/MCAM, which can be used to enrich BM-MSCs cultures, has been proposed for isolation of functionally homogenous MSC populations.25

This set of markers is not exclusively expressed by MSCs, some of them are indeed shared (ie, with fibroblast) and highly modulated during long-term culture. The lack of unambiguous markers may affect MSC functionality and efficacy between various studies and trials as described below in the following paragraphs.

Besides the expression of surface markers, MSCs are characterized by functional properties such as self-renewal and multilineage differentiation. MSC cultures undergo chondrogenic, osteogenic and adipogenic lineage differentiation when standard protocols are used, but other specific differentiation media can promote smooth muscle and striated muscle phenotype26 and expression of cardiac and liver genes.27 Typically, in vitro, BM-MSCs can differentiate into adipocytes, osteoblasts, or chondroblasts28 after exposition to specific stimulating factors (ie, dexamethasone for osteogenic differentiation; TGF-β and high cell-density for chondrocytes; and dexamethasone, insulin, isobutyl methyl xanthine, and indomethacin for adipocytes) for 1 to 3 weeks. Confirmation of trilineage differentiation is a valuable basis to verify MSC identity from different tissue origin which, however, may diverge for differentiation potential29 and show a species-dependent plasticity.30 Moreover, cellular heterogeneity of the cultures, likely including also committed cells or progenitors, makes differentiation capacity not identical among MSC cultures, limiting multiple lineage differentiation.31 Therefore, the translatable in vitro biological features into in vivo effects may not be as clear-cut as could be expected.

A better definition of surface markers and global molecular signatures of MSCs will help to determine and predict their effective multipotency.

However, because MSCs display high plasticity and can form any cell type, other studies indicate that alternative in vitro conditions can trigger MSC transdifferentiation into multiple cell lineages, such as cardiac,32 muscle,33 endothelial cells,34 astroglia,35 pancreatic islet cells36 renal tubular epithelium,37 keratinocytes,38 and hepatocytes.39 However, reliability and significance of MSC differentiation into mesodermal and nonmesodermal lineages is still highly controversial, and there is no evidence that occurs in vivo.

1.3 Overview of MSC functional properties

MSC peculiar biological properties have been exploited for stem cell-based therapeutic approaches both in preclinical and clinical studies. The favorable properties such as extensive proliferation, multipotency, ability to migrate and home to the site of injury or inflammation, and immune-modulation boost MSCs use in regenerative medicine, and as vehicle for gene and drug delivery into diseased areas. As therapeutic agents, MSC can act directly by cell-cell interactions or indirectly, by secreting factors (growth factors, chemokines, cytokines, exosomes), which modulate cell and tissue functions.

In vivo, MSCs display complex biological features and behavior highly dependent on their genetic profile and the surrounding microenvironment of the anatomic sites in which they reside that are formed by different cell types and extracellular matrix (ECM) composition. Therefore, both humoral and cell-cell signaling mechanisms control MSC growth, mobilization, and differentiation.

MSC ability to migrate and accumulate into inflamed, ischemic, or injured tissues, as well as in tumors, contributes to tissue repair or regeneration. MSC homing has been definite as the active or passive
arrest within vasculature followed by transmigration across endothelium.\textsuperscript{40} Regenerative medicine mainly exploits MSC differentiation to support heart and lung tissue injury repair; nevertheless, the therapeutic efficacy is often debated due to the incomplete cell characterization, and the inconsistent in vivo viability, distribution and engraftment. Preferential MSC homing to damaged/inflamed sites in vivo is steered through a gradient of chemokines released from the injured sites, using a leukocyte-like multistep extravasation, following a cascade process by rolling, activation, firm adhesion, and transmigration.\textsuperscript{41} This multistep mechanism involves several molecules (eg, CXCR4/7, VLA-4, ICAM-1, CD44, matrix metalloproteinases [MMPs]) (for a review, see Reference 42). Homing is finalized by migration steps by which MSCs reach, through the interstitium, the injured areas, further favored by other chemotactic cues released by both damaged tissues and immune cells, including growth factors (vascular endothelial growth factor [VEGF], platelet-derived growth factor [PDGF], insulin-like growth factor 1 [IGF-1], fibroblast growth factor [FGF]), cytokines and chemokines (CXCL12, CXCL8, CCL5, etc.).

In vivo, besides local factors (ie, chemokine gradient), this process depends also on the site of infusion, which implies the requirement of bypassing systemic vascular barriers to reach the target tissue. In fact, MSCs can be dispensed either by site-specific or systemic administration, through intravenous, intraperitoneal, or intra-arterial infusion. After intravenous inoculation, the vast majority of MSCs is rapidly trapped within the capillary beds in the lungs, due to MSC size and volume, which are bigger than lymphocytes, a phenomenon termed “first-pass” effect. Intra-arterial infusion bypasses the “first-pass” effect, allowing MSCs to spread peripheral tissues before to reach lungs.\textsuperscript{43} Of note, endogenous BM-MSCs are smaller in size than ex vivo in vitro-expanded MSCs.\textsuperscript{44} Conversely, MSC tropism seems not to be limited by the blood-brain-barrier (BBB), formed by cellular interactions between astrocytes, pericytes, neurons, and microvascular endothelial cells.\textsuperscript{45}

However, the molecular mechanisms responsible for MSC brain homing have not yet entirely elucidated. Several in vivo studies demonstrate MSC presence in xenograft glioma models, after either direct or systemic inoculation. In support to MSC ability to reach gliomas, several imaging methods were developed that allow to visualize and track MSC migration in vivo, from single cell level to whole body. Lipophilic fluorescent vital dye labeled MSCs, injected into the carotid artery or in the opposite cerebral hemisphere of mice bearing human glioma intracranial xenografts, were visualized through immunohistochemistry analysis of brain tissues at single cell level.\textsuperscript{46} Ex vivo histological detection of MSCs in the target tissues is the most common method used exploiting a large number of fluorescent vital dyes.\textsuperscript{47-49} Alongside these techniques, whole body imaging methods have been developed and allowed to study the kinetics and the distribution of MSCs in live animals. The main and most used are bioluminescent optical imaging (BLI), magnetic resonance imaging (MRI), and nuclear imaging techniques.\textsuperscript{50-55} For a in-depth review on MSC homing imaging, see Reference 43. In a syngeneic rat model, luciferase charged MSCs, injected in the right common carotid artery, were tracked by in vivo BLI into right frontal lobe, co-localizing with glioma cells. Similar results were observed using a fluorescent vital dye, after injection into the same site. However, no homing was detected when MSCs are intravenously injected.\textsuperscript{51}

Homing of MSCs to human brain tumors was studied comparing three main imaging methods. Fluorescent vital dye, luciferase, or ferumoxide charged MSCs were analyzed by BLI or MRI or immunofluorescence for homing U87 glioma mice xenografts. Contralateral migration of forebrain inoculated MSCs was detected with all three imaging systems, pointing out the useful application of all the techniques and in particular of MRI to increase imaging resolution and estimate real-time migration.\textsuperscript{53} Other technical studies validate the use of gold-coated nanoparticles or ferritin heavy chain expressing MSCs as marker to track by MRI.\textsuperscript{50,54} Migration of AT-MSCs to target brain tumor-initiating cells was studied by in vivo BLI analysis using fluorescent magnetic nanoparticles.\textsuperscript{52,56} Hsu et al demonstrated that hypoxia-preconditioned placental-derived MSCs (p-MSCs) pass BBB and reach intracranial U87-GBM stem cells in mice. They monitored tumor homing of intravenously injected p-MSCs charged with PEG-SPIO nanoparticles through T2-weighted MRI, a real-time and noninvasive imaging method. Nevertheless, most of intravenous injected p-MSCs were trapped in the lungs.\textsuperscript{52} Lung entrapment and cell administration remains the main issues interfering with MSC homing and consequently MSC drug delivery, thus approaches to improve these processes (ie, reduction of cell diameters; increase capillary permeability; use of microparticles charged with MSC secretoma; use MSC-derived EVs or exosomes) are important challenges to deal with.

A mutual influence exists between migratory and immunomodulatory proprieties since immune-related factors released by MSCs regulate immune response and simultaneously MSCs are affected by paracrine modulation of immune cells (T and B lymphocytes, NK cells). This aspect increased the interest about MSC application in immune diseases, and currently their paracrine modulation of tissue cell functioning is gaining a broader perspective on MSC-based therapy scene rather than cell replacement approaches.

MSCs exert immunomodulatory activity on both the innate and adaptive immune systems. Direct or paracrine interaction between MSC and immune cells can impair immune activity via PDL-1 and Fas-L, and through TGFβ, HGF, and PGE\textsubscript{2}, respectively. Immunosuppressive effects are related to the inhibition of T-cell proliferation and induction of Tregs,\textsuperscript{57,58} promoting macrophages transformation from M1 to M2 anti-inflammatory phenotype,\textsuperscript{59} or contributing to immune homeostasis. MSCs also modulate maturation and functions of dendritic,\textsuperscript{60} B,\textsuperscript{61} and NK cells.\textsuperscript{62} However, as for other proprieties of MSCs, also observations on the immunosuppressive effects mainly derive from preclinical models, therefore, the clinical translation, showing divergent data of efficacy, is far from be definite.\textsuperscript{63}

Overall, the biological properties of MSCs evidence a perspective role in oncology, based on their innate tumor tropism and release of relevant factors to modulate tumor microenvironment (TME), also considering genetically modified and loaded MSCs able to transport and deliver therapeutics to cancer sites. In this context, the oncogenic risk and pro-metastatic effects represent crucial limitation factors for clinical applications.\textsuperscript{64,65}
MSCs IN THE TME: THE UNICITY OF GBM

MSCs display stem properties that support their self-renewal and regenerative functions and simultaneously represent a helpful component for survival and proliferation of other cell types and stem cells within their specialized microenvironment, the stem cell niche.

Human BM-MSCs reside in specific niches including nonhematopoietic cells (osteoblasts, adipocytes, endothelial cells) that sustain and regulate throughout life the hematopoietic compartment and osteoblasts, as either regenerative response or homeostasis of the stem cell pool.

Stem cell niches are almost ubiquitously distributed in adult tissues as well the presence of MSCs, particularly in perivascular niches harboring MSCs resembling pericytes, have been described in multiple organs, consistently with the ubiquitous distribution of capillary blood vessel. This localization might be due to the vascular/blood support and MSC recruitment needed during regenerative processes. However, the lack of peculiar markers to discriminate MSCs from pericytes, and their similarity to BM-MSCs makes challenging their exact characterization, even if a common developmental derivation for perivascular MSCs could be hypothesized.

Interestingly, perivascular MSCs also reside in the human brain tissue, within neuro-vascular niches, with endothelial cells, astrocytes, and neurons as well as in mouse brain, where MSCs, morphologically similar to BM-MSCs, have been described.

There is increasing evidence of the critical involvement of MSCs in the TME, and therefore in cancer development and progression. MSCs are recruited within tumors and tightly interact with the other cell types present in the TME, since tumor site is affected by a chronic state of inflammation. Thus MSC homing, fate and reprogramming is driven by cues produced by diverse resident cells composing the tumor stroma (endothelial cells, fibroblasts, pericytes, adipocytes, immune cells), cancer cells, and cancer stem cells (CSCs). CSCs are slowly dividing cells, display a highly invasive phenotype, and are considered the “root” of cancer recurrence.

MSCs exposed to tumor cell-conditioned medium can differentiate into cancer associated fibroblasts (CAF) by TGFβ1-mediated mechanisms, promoting tumor invasion, epithelial-mesenchymal transition (EMT), ECM modification, and cancer cell stemness, leading to tumor progression and metastasis.

In particular, a back-and-forth crosstalk between MSCs and CSCs has been shown in several tumor types; for example, in breast cancer this interaction can transform MSC into tumor-forming cells.

MSCs have been identified in the stroma of many cancers, including human GBM, likely deriving from local sites or being recruited from BM, and represent, altogether with other nonneoplastic stromal components (endothelial cells, pericytes, immune cells, and glial cells), about 50% of GBM mass.

GBM, the most common and aggressive brain primary cancer, despite surgery, radiation, and chemotherapy, is invariantly lethal. GBM represents the paradigm of the role of tumor-initiating CSCs in the promotion of tumor aggressiveness, cell heterogeneity, and drug resistance. All these glioblastoma stem cell (GSC) functions are tightly regulated by autocrine/paracrine activation of chemokine receptors (ie, CXCR4/CXCR7), and by TME. In detail, GSC self-renewal is sustained by reactive tumor-associated microglia and macrophages, astrocytes, endothelial cells and other cell types present in the niches, MSCs included, which thus contribute to tumor recurrence and therapeutic resistance.

Interestingly, in the WHO classification, which divide GBMs in proneural, neural, mesenchymal, and classical subclasses, the majority of GBMs has a mesenchymal phenotype, identified by the incorporation of peculiar molecular signatures (IDH status, ATRX loss, H3K27M mutation, TP53 mutation, 1p/19q codeletion). The clinical behavior of mesenchymal GBMs is extremely aggressive, with resistance to radiotherapy and the poorest prognosis as compared to all the other subtypes. In addition, also GSCs from this subgroup of GBM express mesenchymal markers, being highly positive for CD44 and BM1, and negative for CD133. The evolution of GBM toward the mesenchymal phenotype is pushed by several factors, including stromal and immune cells within the TME, and a selective pressure induced by radio-chemotherapy.

Therefore, MSCs and mesenchymal phenotype directly and indirectly (via TME) contribute to the striking intratumor heterogeneity of GBM cells, likely supporting high cellular plasticity, GSC survival to therapeutic agents and tumor progression. The presence of MSC-like cells within GBM stroma (GBM-associated MSCs [GA-MSCs]) reveals the crucial role played by these cells in GSC proliferation and tumorigenicity. Tumorigenic MSC-like cells, have been identified in GBM specimens, located around vessels in the vascular niche, by the expression of mesenchymal markers (Lin-Sca-1, CD9, CD44, CD166) and for the differentiation potential.

GA-MSCs can be recruited either from local brain sources or from the BM. BM-MSCs have high affinity for GBM and enhance GSC self-renewal and invasive potential; a subset of these tumor-supporting stem cells, identified in both low and high-grade gliomas, was reported to be able to sustain the aggressiveness of GSCs via exosome release and its presence represents a predictive parameter of bad prognosis.

However, the phenotype of GA-MSCs and BM-MSCs often do not completely overlap, since, besides peripherally recruited MSCs, others GA-MSCs may origin from CSC differentiation and display genetic patterns intermediate between these two cell populations, in term of marker phenotyping (ie, differential expression of CD90), origin (differentiation of GBM cells) or function. Therefore, different mesenchymal populations are present within GBM mass.

Several findings suggest that MSCs are involved in angiogenesis, further contributing to the malignancy of gliomas. The ability of GA-MSCs to differentiate into pericytes, driving the maintenance of functional vessels essential for GBM growth, has been also
microenvironment where they are analyzed. Therefore, it is relevant to study the cross talk between MSC and GBM cell populations and in particular, how MSC secretome changes after cocultures with cancer cells.

A comparative analysis of the major studies analyzed in this review is reported in Table 2.

### 3.1 Direct MSC-GBM cell-to-cell interaction

The cross talk between MSCs and GBM cells, besides protein and vesicular component exchange, is strictly dependent on and sustained by their close contact that is established in the TME. GA-MSCs, as key components of GBM stroma, promote proliferation, stemness, and tumorigenicity of GSCs, through the release of IL-6 and the activation STAT3 in cancer cells. Most GA-MSCs isolated from human GBM tissues are genetically distinct from the GSC paired, although some of them may derive from GSC differentiation.

In a murine syngeneic GBM model, GL261 cells, inoculated into the brain, recruit MSCs from host to the tumor site, and the presence of MSC infiltration correlates with tumor progression. GA-MSCs show a definite mesenchymal phenotype (Sca-1+/CD9+/CD44+/CD166+) that is also expressed by GL261 cells.

Su-Jae Sun’s group focused its studies on the role of GA-MSCs in the remodeling of ECM favoring the invasion of GBM cells, through hyaluronic acid (HA) deposit in the microenvironment. This occurs via an autocrine mechanism regulated by C5a secretion, which, in turn, activates HAS2 receptor and ERK1/2 MAPK to cause HA release. GA-MSC modifications of GBM microenvironment are also dependent on CCL2 release, which mediates the activation of JAK1 to regulate actin-myosin contractility and TME and tissue mechanical stiffness needed to promote the motility of tumor cells. Therefore, GA-MSC contribute to ECM remodeling modifying GBM stiffness similarly to what CAFs do in carcinomas. Recently, the same authors reported that C5a released by GA-MSCs increases ZEB1 levels in GBM cells through the activation of C5aR1 and p38 MAPK signaling, promoting the invasiveness of GBM without modifying growth rate in vitro. C5a secretion is increased by coculture with GBM cells pointing out a cross talk between GA-MSC and GBM. Conversely, BM-MSC co-inoculated with GBM cell neither release C5a nor modify tumorigenesis and mice survival, revealing an intrinsic difference between GA- and BM-MSC origin although both cells types express the same mesenchymal markers and differentiation ability.

It is generally accepted that the serum-free culturing conditions preserve GSC tumorigenicity, while the presence of fetal serum in the culture medium allows the development of nontumorigenic cells causing the depletion of nonadherent tumorigenic population. However, by interaction with MSCs, GSCs are able to retain their tumorigenic ability. In fact, it has been reported that in a mixed cell culture, adherent mesenchymal-like cells may act as feeder layer to allow nonadherent GSCs to grow also in the presence of serum, retaining the tumor stem-like features.
| MSC source  | GBM cell model | Study type | MSC-GBM interaction | Study results | Anti-tumorigenic effects | Reference |
|-------------|----------------|------------|---------------------|---------------|--------------------------|-----------|
| UCB-MSC     | U87 GBM#1      | In vitro   | Indirect            | UCB-MSC: inhibition of cell growth | AD-MSC; promotion of cell growth and angiogenesis, inhibition of apoptosis | Akimoto et al |
| AD-MSC      | GBM#12         | In vivo    | Direct              |               |                          |           |
| UC-MSC      | *CSC1 CSC2 CSC3* | Yes No | Yes Yes | Direct co-culture inhibits cell growth | CM promotes cell proliferation | Bajetto et al |
| Fetal BM-MSC | U251            | Yes No No Yes Yes | CM: no effect | Co-culture induces early stimulatory effects on cell proliferation, later inhibitory activity | Chistiakova & Polianskaia |
| Fetal M-MSC | SNB-19 4910     | Yes Yes No No | Induction of cell apoptosis by downregulation of XIAP | Dasari et al | |
| UCB-MSC     | U251 SNB-19     | Yes Yes No No | Reduction of tumor volume and vascular density | Ho et al | |
| BM-MSC      | ∆Gli36 NNI32    | Yes Yes Yes Yes | In vitro and in vivo promotion of cell growth and stemness through the IL-6/p130/STAT3 pathway | Hossain | |
| GA-MSC      | GSC             | Yes Yes Yes Yes | CM induces cell cycle arrest, downregulation of cyclin D1, senescence and increases TMZ sensitivity | Kolosa et al | |
| BM-MSC      | X01             | Yes Yes Yes Yes | Enhancement of invasiveness by HA deposition via autocrine C5a/ERK1/2/HAS2 activation | Lim et al | |
| BM-MSCs UC-MSC | NCH421k NCH644 NIB26 NIB50 | Yes No Yes No | Pro-invasive matrix remodeling by CCL2/JAK1 activation and actomyosin contractility | Lim et al | |
| GA-MSC      | X01             | Yes No Yes Yes | Promotion of invasiveness through Ca5, p38/ZEB-1 axis | Lim et al | |
| BM-MSC      | X01 TS11-16 TS09-03 | Yes Yes Yes Yes | No effects on cell growth, stemness and TMZ sensitivity, increase of cell migration | Onzi et al | |
| AD-MSC      | U87 U87-CSC     | Yes No Yes No | | | |
| MSC source | GBM cell model | Study type | Study results |
|------------|----------------|------------|---------------|
| UC-MSC     | U87            | Indirect   | Increase of cell proliferation. Cell–cell contact enhances proliferative and invasive cell behavior and tumor development in vivo | Rodini et al<sup>126</sup> |
| BM-MSC     | U87 U373       | Direct     | Inhibition of cell proliferation and migration; syncytium and fusion formation | Schichor et al<sup>113</sup> |
| BM-MSC     | SU3            | Indirect   | Cell fusion contributes to GBM neovascularization | Sun et al<sup>112</sup> |
| BM-MSC     | SU3            | Direct     | In vivo, cell fusion enhances angiogenesis | Sun et al<sup>112</sup> |
| UCB-MSC    | U251 S310      | Yes        | Induction of cell cycle arrest through cyclin D1 downregulation | Velpula et al<sup>115</sup> |
| UCB-MSC    | U87 U251 4910 S310 | Yes        | Reduction of cell invasion and growth; induction of MET; reduction CSC phenotype | Velpula et al<sup>118</sup> |
| UC-MSC     | U251 SNB-19    | Yes        | Increase of cell proliferation, migration, no effects on TMZ sensitivity | Vieira de Castro et al<sup>127</sup> |
| AD-MSCs    | U251           | No         | Inhibition of cell growth by inducing apoptosis and differentiation | Yang et al<sup>122</sup> |
| UC-MSCs    |                |            |               | |

Abbreviations: AD-MSC, adipose MSC; BM-MSC, bone marrow MSC; CM, conditioned medium; CSC, cancer stem cells; ECM, extracellular matrix; GA-MSC, glioma associated MSC; GSC, glioblastoma stem cells; HA, hyaluronic acid; ISCT, International Society for Cellular Therapy; MET, mesenchymal epithelial transition; M-MSC, muscle MSC; UC-MSC, umbilical cord MSC; UCB-MSC, umbilical cord blood MSC; TMZ, temozolomide; XIAP, X-linked inhibitor of apoptosis protein.
The influence of BM-SCs (labeled with green fluorescent protein [GFP]) on GBM development was also addressed analyzing their modulation in coculture with GBM progenitor cells (labeled with red fluorescent protein [RFP]). These in vitro culture conditions induced the fusion of the two populations (identified as GFP+/RFP− cells) that, when injected into mice, transdifferentiated causing the formation of a solid and vascularized tumor in vivo.112 Thus it was proposed that cell fusion may represent a major driving factor for GBM neovascularization. This observation was then confirmed in a more recent paper by the same authors. The injection of RFP-GBM cells into the caudate nucleus of GFP-mice allowed the isolation of GFP+/RFP− cells, representing fused cells. GBM-BM-SCs fused cells showed enhanced endothelial marker expression (CD31, CD34, VE-Cadherin), in addition to stem cell markers, and enhanced angiogenic and tumorigenic ability, as compared to parental glioma cells.113 Conversely, other studies using cocultures of BM-SCs and U87 and U373 glioma cells reported a reduction of proliferation of both populations due to the generation of a synctium between mesenchymal and glioma cells, mainly mediated by gap-junctons. However, although the fusion events are more manifest in cells grown as spheroids than in monolayers, enhanced migration of glioma cells out of spheroids in cocultures was observed as compared with monocultures of either BM-SC or GBM spheroids.113

Rao’s group published a series of studies supporting the ability of human UCB-SCs to reduce GBM growth both in vitro and in vivo. Authors proved that UCB-SCs exert their antitumor action on glioma cell lines inducing apoptosis and cell growth arrest, via downregulation of the antiapoptotic protein XIAP114 and the cell cycle regulatory proteins, cyclin D1 and CDK 4, leading to cell death.115 All these effects were confirmed in nude mice in which the sizes of intracranial xenografted tumor was reduced of about 1/3 after UCB-SCs injection. (It has to be noted, however, that PLoS One Editors116 retract a previous study from these authors on the same topic117 due to concerns questioning the reliability of the reported results). UCB-SCs cocultures were also reported to inhibit GSC growth decreasing SOX2 and Twist 1 expression levels, in addition to other EMT markers. Likewise, in vivo UCB-SCs reduced established glioma grafted in nude mice, modulating SOX2 and Twist 1.118

In our lab, we assessed the direct interference of UC-SCs on GSC cultures isolated from both human neural and mesenchymal GBMs. The study showed that the coculture of 3D-spheroids obtained from each cell type and differentially labeled, favors reciprocal tropism, with the fusions of the spheroids after 4 days in culture. In particular, Dil-labeled UC-SCs migrated into GFP-expressing GSC spheroids, as well as invasion of the red UC-SCs spheroid by green GSCs was evident.119 To determine whether this direct interaction between UC-SCs and GSCs might interfere with tumor growth, GSC proliferation was evaluated using CFDA-SE dye dilution assay by flow cytometry, that allows tracking cell division as sequential halving of initial fluorescence in daughter cells, and by measuring Ki-67 labeling by cytoimmunofluorescence analysis, using cocultures of differentially labeled cells. In both assays, we showed that cell-cell contact reduced proliferation of both UC-SCs and GSCs, without causing cell death.119 A similar approach was also used by Ho and coll., which showed that BM-SCs reduce proliferation of GBM cells using either cell lines (∆Gli36) or primary cultures from biopsies. Moreover, they confirmed these results in vivo, xenografting subcutaneously both cell types in equal ratio, and observed that besides smaller volumes, tumors originated in the presence of BM-SCs were visibly less vascularized. Conversely, tumor growth was not affected by co-plant with immortalized normal human astrocytes.120

Thus, although a direct interference of MSCs on GBM cell growth was reported by different studies causing the activation of cytostatic pathways, cell fusion also favored cell migration and proangiogenic transdifferentiation, highlighting the potential complexity of the use of MSCs as therapeutic agents for GBM.

### 3.2 | Indirect MSC-GBM cell-to-cell interaction: Paracrine effects of released cyto/chemokin

Besides effects mediated by direct cell-to-cell interactions or acting as stem cells, in which differentiation ability allows to replace damaged cells, MSCs can exert physiological (and pharmacological) activities through paracrine mechanisms. However, in many cell systems, this latter mechanism is absolutely predominant and MSC stem cell nature has been challenged. Thus in the recent years several authors modified the definition of MSC into “mesenchymal stromal cells” to underline that in vivo MSCs exert their activity mainly through the secretory function rather than through the differentiation ability, as expected by “real” stem cells.121 MSC secretome is composed of a large population of secreted proteins and peptides and a vesicular fraction, being the latter composed by macrovesicles and exosomes, able to vehicle genetic material. The most common and relevant molecules present in the MSC secretome are cytokines, chemokines and growth factors. For example, in our study, a strong production of molecules involved in inflammation, angiogenesis, cell migration and proliferation, such as IL-8 (CXCL8), GRO-related peptides (CXCL1, 2 and 3), ENA-78 (CXCL5), MCP-1 (CCL2), and IL-6, was observed in UC-MSC cultures.119

Conditioned medium of AT- or UC-derived MSCs was shown to reduce cell proliferation of U251 glioma cell line, as well as in other tumor cell types. This antitumor effect is mediated by increasing apoptosis and stimulating in vitro differentiation of glioma cells.122 Nevertheless, it has been reported that MSCs from different sources can have opposing effect when co-cultured with GBM cells, derived from either primary culture or established cell lines. UC-MSCs inhibit GBM cell growth and cause apoptosis via activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), whereas AT-MSCs promote cell growth. However, the conditioned medium collected from UCB-MSCs did not affect GBM cell growth, suggesting a role for a direct interaction among cells, while that from AT-MSCs supported the proliferation of GBM cells, being the cells enriched in the mRNAs controlling angiogenic factors (VEGF, angiopoietin 1, PDGF, IGF-1, and CXCL12). Subcutaneous co-injection of cells from a GBM primary culture with UCB-MSCs in Matrigel confirmed the
ability of UCB cells to reduce tumor growth, whereas AT-MSCs generate highly vascularized tumors. Thus the authors propose that these differences must be considered when choosing a stem cell source for safety in clinical application.

Paracrine activities of conditioned medium from both BM- or UC-derived MSCs was also reported to cause cell cycle arrest and senescence, in GSCs and GBM primary cultures by reducing cyclin D1, without inducing apoptosis or cell death. MSC secretome promotes differentiation of GSCs, downregulating the stemness markers SOX2 and Notch-1, upregulating the glial markers GFAP and vimentin, and resulting in increased sensitivity to TMZ and 5-fluorouracil (5-FU). MSC-dependent paracrine antiangiogenic effects were also proposed in light of the impairment of the endothelial progenitor cell capacity to form endothelial tubes in the presence of conditioned media derived from MSC/glioma coculture, an effect that was related to reduced PDGF and IL-1 release.

In contrast, a subsequent study reported that AT-MSCs conditioned medium does not influence the proliferation rate and TMZ response in the human GBM U87 cell line, but increases cell migration, without modifying CSC markers expression or spherogenic ability.

In a more recent paper, Rodini et al describe TGFβ as the main cytokine released by UC-MSCs able to stimulate the growth in U87 cells, since its silencing abolishes the proliferative cue of UC-MSC conditioned medium. When co-injected with U87 in nude mice, UC-MSCs increase tumor formation, although in vivo this effect is mediated through a TGFβ-independent mechanism. Thus the Authors explored the changes occurring in the conditioned medium of MSCs co-cultured with U87: regardless from TGFβ expression, 126 proteins with 10 new expressed proteins were identified about 700 proteins with significant enrichment in Wnt, PDGF and VEGF, whose signaling pathways are often dysregulated in cancer. Other interesting proteins released by UC-MSCs included the chemokine CCL2, semaphorin-7A, peristin, and IL-6. Chistiakova and Polianskaia characterized the paracrine activity of the conditioned medium of fetal MSCs, from both BM and muscle origin, in different spatial and temporal conditions. No molecule presents in the secretome of MSCs affected GBM cell growth, whereas the picture changed after direct coculture: the crosstalk between U251-MG glioma cell line and fetal MSCs impair cell growth in the early period of co-cultivation, which turns into cell proliferation after long time of coculture.

A strong relevant effect of the paracrine crosstalk between mesenchymal and glioma cells arises also from our studies. Factors released by UC-MSCs increase GSC proliferation and migration, through the activation of ERK1/2 and Akt signaling pathways, upon CXCR2 activation, since it was reverted by a selective receptor inhibitor. Interestingly among the cytokines released at the highest levels by UC-MSCs, CXCL1, 2, 3 and 5 are CXCR2 ligands. This suggested that the activation of this ligand-receptor pathway may represent a major determinant of the paracrine modulation of MSC on GSC proliferation.

3.3 | Indirect MSC-GBM cell-to-cell interaction: EVs and miRNAs

3.3.1 | Extracellular vesicles

EVs are other important mediators of cell-to-cell communication. In particular, many biological effects of MSC-mediated paracrine signals, in different physiological and/or pathological conditions, involve the release of EVs. EVs are composed by a heterogeneous cell-released particle population, delimited by a plasma membrane-derived lipid bilayer, which contain both transmembrane proteins and cytoplasmic components. EV classification includes, as main components, exosomes and microvesicles (MVs) that differ in size, origin and antigenic composition. Different particle populations can be identified in MSC culture supernatants. In particular, with “small EVs” (sEVs) are defined particles characterized by a diameter ranging about 50 to 200 nm. The commonly used term “exosome” often refers to a specific typology of sEV, generated from the endosomal system, at odds with “ectosomes” (also named as MVs or microparticles) that bud from cell membrane. In detail, intraluminal vesicles are released from cytosol as exosomes when multivesicular bodies fuse with the plasma membrane, thus the identification of sEVs as “exosomes” requires evidence for their origin from endosomal structures, and cannot only be based on size. For this reason, in a therapeutic perspective, the separation and characterization of a pure MSC-exosome preparation requires the removal of the numerous vesicle populations of non-endosomal origin that is extremely challenging to fulfill at this time, and to obtain a pure population is without clinical relevance. Thus the term “sEV” should be adopted when these particles are tested for therapeutic purposes, being agnostic to the site of subcellular origin.

This definition also accomplishes recent recommendations from the Minimal Information for Studies of Extracellular Vesicles 2018 guidelines regarding EV classification, in which physical characteristics or isolation method should be preferred to actual origin (ie, if particles show the ability to pass through a 0.22-μm filter, are pelleted at 100 000g, or are smaller than 200 nm in diameter can be defined sEVs), unless it is established a defined subcellular origin, for example via the detection of specific markers. In this context, irrespectively from biological meanings, a practical classification could include: sEVs (diameter range 30-150 nm), which also comprise exosomes, but not exclusively; MVs (diameter range 50-1000 nm), derived by outward
invaginations of cell membrane, and apoptotic bodies (diameter range 50-5000 nm), which represent fragments of apoptotic cells. Besides a certain degree of confusion in particle definition existing in the studies trying to develop a therapeutic approach using MSC-derived EVs, a further complication also derives from the potential different activity according with the tissue origin of MSCs (see below).

Thus a rather complex scenario is currently present in literature when approaching the biological role of EVs in intercellular communications and, even more seriously, when considered for potential clinical application. Indeed, while the therapeutic application of MSC-derived EVs seems to be simpler than the direct use of whole MSC (ie, as far as production, manipulation and storage, including their engineering to transport pharmacological active molecules, which extend their application fields), several standardization issues are still to be solved to obtain a reliable therapeutic use of these particles.

3.3.2 Therapeutic use of MSC EVs for tumor treatment

EVs may transfer transcripts from MSCs to GBM cells, or vice versa, resulting in reprogramming the respective phenotype. For example, the transfer of transcript from MSCs to GSCs may activate migratory or self-repair abilities. Figure 1 is a representative picture of the intercommunication between MSCs and GSCs via EVs, showing the transfer of red-stained UC-MSC EVs to green-stained GSCs after coculture.

The first evidence of the potential therapeutic role of MSC-derived EVs occurred in trials using whole MSCs to induce immunosuppression in Crohn and graft-vs-host diseases. However, also in the presence of beneficial effects for the patients, MSCs were not proved to persist after administration or directly contribute to the observed activity. Thus a paracrine activity, including the production of EVs, was assumed as mechanism of their therapeutic activity. This hypothesis was confirmed in some models of ischemia-reperfusion injury by injection of MSCs conditioned medium, which showed the same efficiency of the administration of the whole cells.

Following this evidence, the development of MSC EVs as innovative drugs was extended to many pathological conditions including tumors. To date, the main approach tested is the use of MSC EVs as vehicle for cytotoxic drugs or for molecules with potential antiproliferative activity (eg, miRNAs).

However, in agreement with the modulatory effects on cell proliferation observed by the direct MSC-GSC interaction, a direct modulation of GBM cell functioning by interaction with EVs was also reported. Glioma cells in culture are able to uptake sEVs (particle analysis was reported to contain a predominant population with a diameter <150 nm) into the cytosol (measured by both confocal fluorescence microscopy and FACS). Using U87 glioma cell line, it was shown that tumor cells treated with these particles were highly modified in their proliferation rate. However, in this study, a surprising differential effect was observed using EVs isolated from MSCs of different sources. BM- and UC-MSCs-derived particles caused a significant inhibition of glioma cell proliferation (up to 50% reduction of proliferation rate) associated with a high increase in apoptosis (evaluated by FACS as sub-G1 fraction and annexin V/propidium iodide staining). Conversely, particles derived from AT-MSCs caused a slight (but statistical significant) increase in U87 proliferation via a speeding up of the cell cycle (increase of the number of cells entering in S and G2/M phases). This evidence suggests that variability in MSC responses and their released EVs according to the tissue origin, or due to genetic, epigenetic, or environmental factors, which may modulate MSC activity, may contribute to the conflicting data reported in the literature about their ability to affect tumor growth.

However, it is important to remark that MSC-glioma cell communication via EVs is bidirectional. Thus, as it occurs for macrophages and fibroblasts, tumor cells are able to “educate” also MSCs to use their functionality as pro-tumorigenic activity. EVs isolated from U251 glioma cells were shown to induce a tumor-like phenotype in BM-MSCs, which increases cell growth and invasiveness through the modulation of the synthesis of cell cycle-related (PCNA, c-myc) and metastasis-related (MMP-2 and MMP-9) proteins. Moreover, overexpression of CSC markers (CD133 and nestin) was also observed. From a mechanistic point of view, it was proposed that the transformation of BM-MSCs into a tumor-like phenotype by glioma cell-derived exosomes can be ascribed to metabolic activation of the glycolytic pathway, as demonstrated by upregulation of Glut-1, HK-2, and PKM-2, leading to the induction of glucose consumption and generation of lactate and ATP. Indeed, it was shown that secreted or EV-delivered proteins are likely microenvironment-dependent.
example, MSCs, transiently exposed to culturing conditions modified to better model a clinically relevant microenvironment likely occurring in vivo (ie, 1% O2 and serum deprivation), released EVs packaged with increased levels of extracellular-associated proteins, among which fibronectin was the most abundant. Importantly, fibronectin mediates the mitogenic activity of these EVs on SHSY5Y neuroblastoma cells. This effect was mediated through the stimulation of the release of several growth factors (VEGF, PDGF, FGF-7, hepatocyte growth factor) by the EV-exposed SHSY5Y cells.148

Thus, the glioma-dependent MSC conditioning represents another potentially clinically relevant variable to be considered when MSCs are planned to be used as therapeutic agents.

### 3.3.3 Cargo analysis of MSC EVs

To shed light on the issue of which proteins and/or nucleic acids are transmitted via MVs, several proteomic studies were performed on MSCs and MSC-derived EVs trying to identify possible molecular components responsible for such effects.

Comparison of BM, UC, AT, and placental MSC proteomic profile identified similar expression pattern as far as several stemness-related genes (Oct4, Sox2, etc.) but a differential immunomodulatory activity, which was shown to be more pronounced in BM-MSCs and AT-MSCs, likely due to the higher expression and secretion of IL-10 and TGFβ.149,150 Similarly, BM-MSCs were more active than AT-, or lung-derived MSCs, to inhibit eosinophil infiltration, and IL-4, IL-13, TGFβ, and VEGF content in experimental models of asthma determining higher therapeutic effects as far as lung inflammation and fibrosis.150

Consequently, also MSC-derived EVs are expected to display a different content according to tissue origin, as far as proteins (including transcription factors) and both coding and noncoding miRNAs (including miRNAs). However, it is not possible to extrapolate data from cell analysis to obtain information on the EV content. MSC exosomes contain only 2% to 5% of the total small RNAome of the original cells and contain only 2% to 5% of the total small RNAome of the original cells and are present at high levels only few miRNAs, irrespectively from the cellular content (human BM-MSC and AT-MSCs were analyzed).151

To date, beside discrepancies in the expression between cells and EVs miRNA content, different studies reported a variety of individual molecules overexpressed or downregulated in EVs. For example, in the previously cited study, miRNAs highly expressed in MSC EVs, in comparison to the parental cells, are: (a) miR-191, miR-222, miR-21, let-7a, known to control cell proliferation; (b) miR-222, miR-21, let-7f involved in angiogenesis; and (c) miR-6087 controlling endothelial differentiation.151 EVs were also reported to contain regulators of transcription associated with the differentiation status of MSCs, as defined by Sox2, POU Class-2 Homeobox 1 (POUSF1A/B), and Nanog, being, in this case, mainly tRNAs, and showing striking differences between BM-MSC and AT-MSCs.151 In a similar study, however, among a total of 413 miRNAs enriched in EVs as compared to parental AT-MSCs, overexpression included miR-183, miR-378, miR-140-3p, and miR-222 whose targeted genes are mainly involved in the modulation of transcription factors such as SMAD Family Member 2 (SMAD2), POU2F1, MDM4, PS3 Regulator (MDM4), and One Cut Homeobox 2 (ONECUT2).152

### 3.3.4 miRNAs

Up or downregulation of specific miRNAs have been more and more involved in the development of several tumors.153 For example, increased expression of miR-199a in tumor-associated MSCs enhances tumorigenic properties of breast cancers.154 miR-221 released from MSCs derived from gastric cancer increases tumor cell proliferation and migration.155 On the other hand, miRNAs belonging to let-7 family are downregulated in prostate cancer-derived MSCs.156

In all these cases, it was shown that normalization of the miRNA expression/secrection abolished the tumor-promoting properties of cancer-derived MSCs, providing a proof-of-concept of the causal relationship between alteration of miRNA activity and the biological effects on tumor cells. Alteration of miRNA production/activity was also demonstrated in GBM. Tumor-educated GA-MSCs, isolated from human GBM surgical specimens, release exosomes, which highly increased GSC proliferation in vitro and tumor growth after xenografting of GSCs in immunodeficient mice.157 Interestingly, no effects were observed treating cells with GSC-isolated exosomes. Analysis of the purified exosome fraction content demonstrated that while cytokines and growth factors were below detection threshold of the array used, it was enriched in several miRNAs. In particular, miR-1587 was identified as a major mediator of exosome effects on GSCs, in part acting through the downregulation of NCOR1, a nuclear receptor corepressor with tumor-suppressor activity.157 These results identify a relevant mechanism by which GA-MSCs sustain tumor growth, and recognize the intercellular transfer of specific miRNAs (ie, miR-1587), via exosome release as mechanism that enhance GBM aggressiveness.

Importantly, administration of exogenous miRNAs is potentially endowed with antitumor activity.153 In particular, due to peculiar biological features, MSCs can be engineered to deliver specific antitumor miRNAs to GBM cells, after being enveloped in exosomes and released.

Several studies addressed this issue and significant examples, but not an exhaustive analysis, here is reported. The identification of miRNAs with potential antigenia activity started from the observation that several of them are downregulated in GBM, and particularly low levels of miR-145 and miR-124 are often detected.158 For example, UC-MSCs can transfer exogenous miR-124 to U87 GBM cells via exosomes, and mediates the inactivation of the target gene CDK6, decreasing the migration ability and enhancing chemosensitivity to TMZ of GBM cells.159 In another study, MSCs were transduced with a lentivirus vector expressing miR-124a and showed that high levels of miR-124a were specifically accumulated within exosomes.160 In vitro, GSC treatment with exosomes from transduced cells caused reduction of viability and clonogenicity. Deliver of exosomes containing miR124 to mice bearing intracranial GSC-induced GBM resulted in long-term survival in 50% of the animals, in which no histological evidence of
tumor was present. Mechanistic studies showed that miR-124a acts by silencing Forkhead box (FOX)A2, which renders GSCs unable to efficiently metabolize lipids, which intracellularly accumulate to reach toxic levels.

These data suggest that MSCs may act as natural biofactory for exosomes carrying miR-124a with antitumor potential. The EVs secretion of MSCs has been exploited to deliver synthetic miR-124 and miR-145 mimics to impair GSC self-renewal and migration through the inhibition of the expression of SCD-1 and Sox2. Importantly, MSCs were able to deliver miR-124 mimic to GBM xenografts, when intracranially administered. A different targeted miRNA is miR-4731, previously identified as tumor suppressor, since it is downregulated in human tumors, including GBM, and its overexpression can lead to the inhibition of cell proliferation and invasion. miR-4731 was overexpressed in AD-MSCs via lentiviral infection. In coculture, AD-MSCs delivering miR-4731 lead to a decreased U87 and U251 GBM cells proliferation, and cell migration and induced apoptosis.

The transfection of MSCs with a plasmid containing miR-146b, known to reduces EGFR expression in glioma cells as well as invasion, migration, and viability, lead its accumulation in exosomes. Intratumor injection of MSC-transduced exosomes significantly reduced glioma xenograft growth in a rat model of primary brain tumor. miR-133b was also reported as an inhibitory regulator of GBM growth targeting the Enhancer of Zeste 2 (EZH2) gene often upregulated in GBM tissues and GSCs. In different studies, MSC-derived exosomes carrying miR-133b, miR-375, or miR-584-5p from transfected MSCs, repressed GBM cell proliferation, invasion, and migration in vitro and in vivo, through the downregulation of EZH2 and the Wnt/j-catenin signaling pathway. Moreover, BM-MSCs overexpressing TRAIL and miR-7, injected in the tail vein of U87 GBM-bearing mice released miR-7-enriched exosomes and suppressed tumor growth through a miR-7-dependent sensitization to TRAIL-mediated apoptosis. Finally, it was shown that TMZ resistance in GBM U87 and T98G cell lines, as well as in GSC cultures isolated from human tumors, was associated to the overexpression of drug efflux transporter P-glycoprotein, induced by high levels of miR-9. Thus BM-MSCs were induced to express anti-miR-9 and tested for the ability to affect GBM cell growth in vitro. These experiments showed that in coculture GBM cells recovered TMZ sensitivity, due to the transfer of the anti-miR-9 from BM-MSCs to tumor cells via exosome secretion.

Overall, MSC delivery of miRNA or the cell vehicle can induce opposite results.

4 | THE POTENTIAL OF MSC-BASED THERAPY FOR GBM

Tumor-tropic capacity of MSCs gained attention also as a tool to deliver cytotoxic agents into cancer sites. Easy viral vector transduction, extensive protein production and expansion in vitro as well as their immune-inert feature, associated, in the brain tumor context, with their ability to cross the BBB, favor MSC genetic engineering. Cytotoxic effects of MSC loaded with different anticancer drugs, were also prepared using liposomes and nanoparticles.

BM-MSCs were loaded with paclitaxel and tested on T98G glioma cell proliferation in vitro. It was shown that the drug was incorporated in a sufficient amount released at cytotoxic effective concentrations when located in the proximity of the cancer cells, despite a 20% loss of cells due to spontaneous apoptosis. In vivo, the treatment with paclitaxel-loaded MSCs of mice carrying GBM xenografts showed a high tropism of MSCs toward the tumor cells, and the ability to cause drug-dependent cytotoxicity, without interfering with normal astrocyte viability.

In another study, BM-MSCs were primed with sorafenib without significant toxicity and were showed to be able to release up to 60% on the loaded drug. These modified MSCs were intranasally administered to mice xenografted with U87 glioma cells, 6 and 10 days after U87 cells. Analysis of the tumors after 1 week from the second MSC injection (17 days after U87 xenograft) showed a lower level of tumor angiogenesis when compared to unprimed MSCs or sorafenib alone, but no change of tumor volume was observed. The authors attributed this lack of activity to low protumorigenic properties observed administering unprimed MSCs, which balanced the cytotoxic effects of sorafenib.

Human MSCs were also engineered to express on the plasmamembrane a single-chain antibody directed against EGFRvIII, a genetic determinant of de novo GBMs, to increase cell selectivity and enhance treatment efficacy. EGFRvIII-expressing orthotopic U87 gliomas were developed in vivo; mice intracranially treated with modified MSCs showed significantly improved survival compared to untreated animals or injected with control MSCs. MSCs, genetically modified to express cytokines, were reported to alter the immunosuppressive microenvironment in GBM models, as observed after intratumoral administration of MSCs co-expressing high levels of IL-12 and IL-7 in mouse GBM, which reduced tumor growth and induced a broad tumor-specific immune response. MSCs expressing adenoviral-mediated IL-18 also impair tumor growth in rat glioma models. UCB-MSCs were also modified to overexpress CXCR4 to increase their tropism toward GBM cells, which release its ligand CXCL12. These modified cells showed a higher migration capacity in vitro, as compared to parental MSCs, and, more importantly, exhibited enhanced migration to tumor cells in intracranial glioma xenografts.

Other MSC engineering strategies, assayed the possibility to deliver suicide protein, the virus-based cytotoxicity, and anti-angiogenic gene therapies. MSCs were transduced with the gene encoding pro-drug-activating enzymes (suicide proteins), such as the herpes simplex virus thymidine kinase (HSV-TK), cytosine deaminase/5-fluorocytosine or rabbit carboxylesterase, which subsequently converted the pro-drug (ie, ganciclovir) in the active molecule with anticancer activity. This approach has been tested in human and rat GBM models. A recent in vivo study describes the peritumoral
and intratumoral homing of MSCs when injected in the contralateral hemisphere in an orthotopic GBM mouse model. Moreover, intratumoral release of HSV-TK from transduced BM-MSCs followed by ganciclovir administration, reduced tumor growth and prolonged mice survival. Analogously, HSV-TK-expressing UC-MSCs limit U87 GBM xenograft growth, although a high UC-MSC/HSV-TK/U87 ratio was required to exert a maximal effect.

Virus-based therapy allows the supply, through MSCs, of genetically modified cytotoxic viruses to selectively kill cancer cells. A phase I trial study is currently recruiting patients with recurrent high-grade glioma to test best dose and side effects of allogeneic BM-MSCs, loaded with the oncolytic adenovirus, dnx-2401, administered via intra-arterial injection (NCT03896568). Other oncolytic adenoviruses, CRADs and Delta-24-RGD, have been used for this strategy in preclinical and clinical studies to test the effective delivery to intracranial tumors. For example, testing different delivery means, it was shown that MSCs migrate and deliver CRAD to distant glioma cells. Similarly, intra-arterially injected MSCs, expressing Delta24-RGD, reach orthotopic U87 or U251 glioma xenografts, release Delta24-RGD into the tumor, and improved survival and tumor eradication in subsets of mice.

UC-MSCs and AT-MSCs, transduced to express the pro-apoptotic molecule TRAIL, were able to reach the tumor and induce cytotoxic effects on both GBM cells and xenografts, without showing evidence of mesenchymal differentiation after injection. Moreover, mouse irradiation before TRAIL-secreting UCB-MSC injection synergistically enhanced apoptosis in both TRAIL-responsive and TRAIL-resistant GBM cells, due to an upregulation of death receptor-5 and activation of caspase pathways. Patient-derived GBM cell apoptosis has been also shown in mice xenografts using a polymeric nanoparticle nonviral transfection for TRAIL expression in AT-MSCs.

Finally, MSCs loaded with paclitaxel-encapsulated poly(D,L-lactide-co-glycolide) nanoparticles were tested in an orthotopic GBM rat model. Modified cells did not show changes as far as migration capacity, cell cycle progression, or multilineage-differentiation potential, but displayed sustained paclitaxel release, both as free molecule and as nanoparticle encapsulated form. When contra laterally injected in the brain of C6 glioma bearing rats, nanoparticle-loaded MSCs were identified within the tumor mass for 2 days after the injection. After 7 days from the injection, tumors of treated animals showed significant higher cell destruction and damaged areas showing signs of necrosis and apoptosis that control animals. Moreover, a prolonged rat survival was observed.

The strong interest in exploiting the tumor-homing ability of MSCs to target tumor cells is increasingly improving the genetic manipulation of these cells, to optimize their migration and effectiveness; however, the underlying mechanisms sustaining tumor tropism and antitumor activity, likely dependent on MSC origin and context-dependent effects, are not completely understood and will require further studies.

As alternative approach, modified EVs from MSCs can be used as selective drug delivery system, although in some circumstances a pro-tumorigenic activity was also reported. Several advantages have been, in principle, identified in the use of EVs. In general, they are quite stable and there is the possibility to freeze them for later use. It is also possible to target them to obtain a directional cell-specific uptake, for example by inducing the expression on the cell of origin of ligands, which can be transferred to the surface of the vesicles and bind to specific receptors on target cells. Thus, high performing exosome purification procedures were developed from WJ-MSC to obtain pure populations, a fundamental condition to adopt these vesicles in clinics. Different approaches can be used to modify EV cargo to use them as precision medicine drug carriers, including overexpression of protein of interest in parental cells, antibody or antigen conjugation, chemical modification, or passive and active loading (co-incubation with free drugs, sonication, electroporation, incubation with saponin, antibody binding). Several approaches were used in this perspective, including EV loading with miRNAs (see previous paragraph) or cytotoxic drugs (doxorubicin, paclitaxel, etc.). Hydrophobic and hydrophilic small therapeutic molecules can be incorporated into EVs, leading, after parental administration, to an improve drug targeting to tumor cells, obtain a slow time-dependent release from the exosomes, and increase in potency and efficacy. While drug delivery, via EVs, and exosomes in particular, was tested in several other tumors there are not relevant studies on GBM. One relevant study was performed in Danio rerio xenotransplanted with U87 glioma cells and using brain cell exosomes loaded with doxorubicin. Exosomes injected into the common cardinal vein of the anesthetized Danio rerio embryos, were able to cross the BBB and enter the brain, reducing tumor growth.

5 | CONCLUSIONS AND FUTURE PERSPECTIVES

Regenerative, immunomodulatory, and tumor-homing properties of MSCs have been exploited to repair tissue injuries, interfere with cancer, immune-based disorder, and neurodegenerative disease development. This large use was also sustained by the relatively easiness of harvest and processing from different sources, and the abundant availability after in vitro expansion. Beyond regenerative medicine, MSC tumor tropism and nonimmunogenicity laid the groundwork for their application in oncology research. In particular, MSCs release soluble factors or EVs that acting via autocrine and paracrine mechanisms are able to modulate cancer cell survival and proliferation, migratory pathways, and induce host immunomodulation.

Despite initial enthusiasm, current literature highlights growing data inconsistencies and divergences on whether and how MSCs may promote or inhibit tumor growth in various cancers, including GBM. Several factors may contribute to contrasting preclinical observations, including MSC tissue of origin, isolation, ex vivo expansion, and culture protocols. Moreover, further complications may derive by the clinical setting, tumor type, administration route, timing, and quantity, often questioning the effective amount of cells homing to tumor site. All these crucial issues, hampering the research reliability and clinical improvement of MSC-based therapies, should be addressed by in-depth studies on biological and molecular properties of these cells.
In the context of GBM, not only MSC effectiveness, but also the key role played by GSCs in tumor initiation, progression and drug resistance point out the need of innovative therapeutic approaches to eradicate this subpopulation. Another challenge of potential MSC-based anticancer treatment is the complexity of the TME in which GSCs exist, where tumor cells and “normal” tumor stromal cells extensively and reciprocally impact on local milieu through secretome, cell-cell interactions, and metabolome alterations (Figure 2).

A new frontier for MSC application is the achievement of genetic engineering-based methodology to convert MSCs into therapeutic vehicles to graft into the tumor and produce or release engineered EVs and nanoparticles, or cytotoxic agents. These strategies supported by some initial preclinical studies, were confirmed in few human cancer studies.

The innovative MSC-based anticancer approaches are juxtaposing with the unresolved basic questions and fixed points on MSC biology, for example, how many typologies of progenitors exist under the MSC acronym, and how can we distinguish them for their functional properties; the definition of standard protocols for MSC expansion in culture; the definition of the most reliable in vitro and in vivo GBM models based either on stable cell line or GSCs. The consolidation of this essential knowledge is the indispensable requirement to understand the crosstalk between MSC and GBM in TME.

Overall, it is clearly perceivable from the literature reported in the present review, as well as from data on the use of MSCs in different disease models and clinical trials, how hard is the comparison of the outcomes between different studies and striking controversies on the successful MSC delivery to target tissues.

Beyond oncology applications, current overwhelming clinical trials using MSCs for multiple diseases, and the simultaneous boosting of industrial interest in MSC-therapies, not always corroborated by reliable clinical effects, warrant warning considerations.

Therefore, before accelerate clinical translation, a step back is needed to focus on the exact MSC nature, to: (a) solve the debate over the misleading MSC nomenclature and define their identity, “stem” or “stromal” identity, to indicate true stem cells or tissue-specific committed progenitors, and to overcame the existing concept of tissue-source equivalence; (b) consider, detect and control cell population heterogeneity which can be isolated from diverse tissues and individual patients; (c) analyze in detail, exploiting genomic and transcriptomic signatures, MSC phenotype and expression profile; (d) define and unify the MSC processing protocols, from the in vitro isolation and expansion steps to the patient treatment.

Due to the complexity of these issues and the absolute require-ment for a standardization of the procedures for MSC isolation and characterization to ensure their optimal application not only in oncology, but also in other therapeutic fields, the constitution of expert panels which can carefully dissect the literature, possibly organized in subgroups according the different application of this cell therapy, are highly recommended. We believe that this approach, establishing a
gold standard in the study and use of MSCs, involving basic and clinical researchers, and even biotech and pharmaceutical companies, could allow a better sharing of information resulting in a real advancement in the field.

CONFLICT OF INTEREST
The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS
A.B., F.B., T.F.: wrote the manuscript; all authors contributed to literature searching, analysis, and critical review of the article cited, and proofread and approved the manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
Tullio Florio https://orcid.org/0000-0002-2394-996X

REFERENCES

1. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641-650.
2. Caplan AI. Adult mesenchymal stem cells: when, where, and how. Stem Cells Int. 2015;2015:628767.
3. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-4295.
4. El Omar R, Beroud J, Stoltz JF, et al. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20:523-544.
5. Witkowska-Zimny M, Wrobel E. Perinatal sources of mesenchymal stem cells: Wharton's jelly, amnion and chorion. Cell Mol Biol Lett. 2011;16:493-514.
6. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103:1669-1675.
7. Manca MF, Zwart I, Beo J, et al. Characterization of mesenchymal stromal cells derived from full-term umbilical cord blood. Cytotherapy. 2008;10:54-68.
8. De Bari C, Dell’Accio F, Tylzanowski P, et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44:1928-1942.
9. Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG. Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg. 1999;65:22-26.
10. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22:649-658.
11. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A. 2000;97:13625-13630.
12. Hass R, Kasper C, Bohm S, et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9:12.
13. Baxter MA, Wynn RF, Jovitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22:675-682.
14. Yang M, Wen T, Chen H, Deng J, Yang C, Zhang Z. Knockdown of insulin-like growth factor 1 exerts a protective effect on hypoxic injury of aged BM-MSCs: role of autophagy. Stem Cell Res Ther. 2018;9:284.
15. Neri S. Genetic stability of mesenchymal stromal cells for regenerative medicine applications: a fundamental biosafety aspect. Int J Mol Sci. 2019;20(10):2406.
16. Nicosia D, Danisovic L. Mesenchymal stromal/stem cell separation methods: concise review. Cell Tissue Bank. 2017;18:443-460.
17. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315-317.
18. Kern S, Eichler H, Stoewe J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294-1301.
19. Lv FJ, Tuan RS, Cheung KM, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32:1408-1419.
20. da Silva Meireles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008;26:2287-2299.
21. Javazon EH, Begg KJ, Flake AW. Mesenchymal stem cells: paradoxes of passing. Exp Hematol. 2004;32:414-425.
22. Ghazanfari R, Li H, Zacharaki D, Lim HC, Scheding S. Human non-hematopoietic CD271(pos)/CD140a(low/neg) bone marrow stroma cells fulfill stringent stem cell criteria in serial transplantations. Stem Cells Dev. 2016;25:1652-1658.
23. Lin G, Liu G, Banie L, et al. Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev. 2011;20:1747-1752.
24. Ning H, Lin G, Lue TF, Lin CS. Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen. Biochem Biophys Res Comm. 2011;411:353-357.
25. Harkness L, Zaher W, Ditzel N, Isa A, Kassem M. CD146/MCAM defines functionality of human bone marrow stromal stem cell populations. Stem Cell Res Ther. 2016;7:4.
26. Gang EJ, Jeong JA, Hong SH, et al. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells. 2004;22:617-624.
27. Bollini S, Pozzobon M, Nobles M, et al. In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev. 2011;7:364-380.
28. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
29. Musina RA, Bekchanova ES, Belayvskii AV, Sukhikh GT. Differentiation potential of mesenchymal stem cells of different origin. Bull Exp Biol Med. 2006;141:147-151.
30. Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res. 2007;327:449-462.
31. Shen X, Pan B, Zhou H, et al. Differentiation of mesenchymal stem cells into cardiomyocytes is regulated by miRNA-1-2 via WNT signaling pathway. J Biomed Sci. 2017;24:29.
32. Miao C, Lei M, Hu W, Han S, Wang Q. A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Res Ther. 2017;8:242.
33. De Angelis L, Borghi S, Melchionna R, et al. Inhibition of myogenesis by transforming growth factor beta is density-dependent and related to the translocation of transcription factor MEF2 to the cytoplasm. Proc Natl Acad Sci U S A. 1998;95:12358-12363.
34. Oswald J, Boxbberger S, Jorgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 2004;22:377-384.
35. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 1999;96:10711-10716.
36. Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol. 2004;10:3016-3020.

37. Li K, Han Q, Yan X, Liao L, Zhao NC. Not a process of simple vicari-ousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev. 2010;19:1267-1275.

38. Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol. 2008;180:2581-2587.

39. Ghaderi Gandomani M, Sahabghadam Lotfi A, Kordi Tamanondi D, Arijmand S, Alizadeh S. The enhancement of differentiating adipose derived mesenchymal stem cells toward hepatocyte like cells using gelatin cryogel scaffold. Biochem Biophys Res Commun. 2017;491:1000-1006.

40. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206-216.

41. Nitzsche F, Muller C, Lukomska B, et al. Concise review: MSC adhe-sion cascade-insights into homing and transendothelial migration. Stem Cells. 2017;35:1446-1460.

42. Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019;15:421-438.

43. Krueger TEG, Thorek DLJ, Denneade SR, et al. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem Cells Translational Med. 2018;7:651-663.

44. Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res. 2009;104:398-402.

45. Liu L, Eckert MA, Riazifar H, et al. From blood to the brain: can systemic administration of human bone marrow-derived mesenchymal stem cells toward glioblastoma stem-like cells in a tumor-specific tropism in an RCAS/Ntv-a glioma model. Mol Cancer. 2018;17:693-702.

46. Krupkiewicz YW, Denham J, Thies RS. Oligodendrocyte progenitor cells derived from human embryonic stem cells express neurotrophic factors. Stem Cells Dev. 2006;15:943-952.

47. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107:367-372.

48. Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009;27:693-702.

49. Li J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824-833.

50. Mohr A, Zwacka R. The future of mesenchymal stem cell-based therapeu tic approaches for cancer - from cells to ghosts. Cancer Lett. 2018;414:239-249.

51. Momin EN, Vela G, Zaidi HA, et al. The oncogenic potential of mesenchymal stem cells in the treatment of cancer: directions for future research. Curr Immunol Rev. 2010;6:137-148.

52. Crisan M, Yap S, Castella L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301-313.

53. Galipeau J, Arjmand S, Alizadeh S. The enhancement of differentiating adipose mesenchymal stem cells contribute to brain tumor progression. J Neurosurg. 2014;128:287-295.

54. Behnan J, Isakson P, Joel M, et al. Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression. Stem Cells. 2014;32:1110-1123.

55. Sun C, Dai X, Zhao D, et al. Mesenchymal stem cells promote glioma neovascularization in vivo by fusing with cancer stem cells. BMC Cancer. 2019;19:1240.

56. Cao M, Mao J, Duan X, et al. In vivo tracking of the tropism of mesenchymal stem cells to malignant gliomas using reporter gene-based MR imaging. Int J Cancer. 2018;142:1033-1046.

57. Doucette T, Rao G, Yang Y, et al. Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia. 2011;13:716-725.

58. Hsu FT, Wei ZH, Hsuan YC, et al. MRI tracking of polyethylene glycol-coated superparamagnetic iron oxide-labelled placenta-derived mesenchymal stem cells toward glioblastoma stem-like cells in a mouse model. Artif Cells Nanomed Biotechnol. 2018;46:S448-e459.

59. Menon LG, Pratt J, Yang HW, Black PM, Sorensen GA, Carroll RS. Imaging of human mesenchymal stem cells: homing to human brain tumors. J Neurooncol. 2012;107:257-267.

60. Qiao Y, Gumin J, MacLellan CJ, et al. Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection. Nanotechnology. 2018;29:165101.

61. Duhrsen L, Hartfuss S, Hirsch D, et al. Preclinical analysis of human mesenchymal stem cells: tumor tropism and therapeutic efficiency of local HSV-TK suicide gene therapy in glioblastoma. Oncotarget. 2019;10:6049-6061.

62. Choi SA, Lee JY, Kwon SE, et al. Human adipose tissue-derived mesenchymal stem cells target brain tumor-initiating cells. PLoS One. 2015;10:e0129292.

63. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.

64. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838-3843.

65. Abumaree MH, Al Jumah MA, Kalionis B, et al. Phenotypic and func-tional characterization of mesenchymal stem cells from chorionic villi of human term placenta. Stem Cell Res. 2013;9:16-31.

66. Li C, Hao Y, Wang X, et al. Reciprocal interactions between human mesenchymal stem cells and mammmal T cells or invariant natural killer T cells. Stem Cells. 2009;27:693-702.

67. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22:824-833.

68. Paul G, Ozen I, Christoffersen NS, et al. The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One. 2012;7:e35577.

69. Koh SG, Shinjoji N, Hossain A, et al. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery. 2010;67:711-720.

70. Berger L, Shanay Y, Skorecki KL, Tzukerman M. Tumor specific recruit ment and reprogramming of mesenchymal stem cells in tumorigensis. Stem Cells. 2016;34:1011-1026.

71. Arena S, Salati M, Sorgontoni G, Barbisan F, Orciani M. Characteriza tion of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer. Clin Transl Oncol. 2018;20:1582-1591.

72. Barcellos-de-Souza P, Comito G, Pons-Segura C, et al. Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-beta1. Stem Cells. 2016;34:2536-2547.

73. Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008;68:4331-4339.

74. Spaeth EL, Dembinski JL, Sasser AK, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One. 2009;4:e4992.

75. Ridge SM, Sullivan FJ, Lynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16:31.
76. Appaix F, Nissou MF, van der Sanden B, et al. Brain mesenchymal stem cells: the other stem cells of the brain? World J Stem Cells. 2014;6:134-143.
77. Melzer C, von der Ohe J, Hass R. In vitro fusion of normal and neoplastic breast epithelial cells with human mesenchymal stroma/stem cells partially involves tumor necrosis factor receptor signaling. Stem Cells. 2018;36:977-989.
78. Worner PM, Schachtele DJ, Barabadi Z, et al. Breast tumor microenvironment can transform naive mesenchymal stem cells into tumor-forming cells in nude mice. Stem Cells Dev. 2019;28:341-352.
79. Hossain A, Gumin J, Gao F, et al. Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the L6-gp130/STAT3 pathway. Stem Cells. 2015;33:2400-2415.
80. Darmanis S, Sloan SA, Croote D, et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 2017;21:1399-1410.
81. Sharifzad F, Ghavami S, Verdi J, et al. Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. Drug Resist Updat. 2019;42:35-45.
82. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
83. Florio T, Barbieri F. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Discov Today. 2012;17:1103-1110.
84. Gatti M, Pattarozi A, Bajetto A, et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013;314:209-220.
85. Dirke A, Golebiowska A, Buder T, et al. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun. 2019;10:1787.
86. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12:1119-1125.
87. Zhu TS, Costello MA, Talsma CE, et al. Endothelial cells create a tumor microenvironment can transform naive mesenchymal stem cells into tumor-forming cells in nude mice. J Neurooncol. 2007;83:241-247.
88. Ochs BS, Verhaak RG, Hoadley KA, et al.; Cancer Genome Atlas Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
89. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173.
90. Birnbaum T, Hildebrandt J, Nuebling G, Sostak P, Straube A. Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. J Neurooncol. 2011;105:57-65.
91. Huang M, Zhang D, Wu JY, et al. Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma. Sci Transl Med. 2020;12 eaay7522.
92. Shahar T, Rozovski U, Hess KR, et al. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017;19:660-668.
93. Rappa G, Mercapide J, Coro D. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am J Pathol. 2012;180:2504-2515.
94. Tumangelova-Yuzeir K, Noyanov E, Ivanova-Todorova E, et al. Mesenchymal stem cells derived and cultured from glioblastoma multiiforme increase tregs, downregulate Th17, and induce the Tolerogenic phenotype of monocyte-derived cells. Stem Cells Int. 2019;2019:6904638.
95. Kim SJ, Kim JS, Park ES, et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia. 2011;13:286-298.
96. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173.
97. Verhaak RG, Hoadley KA, Purdom E, et al.; Cancer Genome Atlas Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
98. Bajetto A, Barbieri F, Marubbi D, et al. Sorafenib selectively depletes tumor-associated mesenchymal stem-like cells promotes the invasiveness of GBM through the C5a/p38/ZEβ1 axis. Neuro Oncol. 2020 Mar 17:nooa064. http://doi.org/10.1093/neuonc/nooa064. Online ahead of print.
99. Bajetto A, Porcile C, Pattarozi A, et al. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility. J Biol Regul Homeost Agents. 2013;27:143-154.
100. Carra E, Barbieri F, Marubbi D, et al. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 2013;12:491-500.
101. Behan J, Stangeland B, Hosainey SA, et al. Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency. Oncogene. 2017;36:570-584.
102. Sun C, Zhao D, Dai X, et al. Fusion of cancer stem cells and mesenchymal stem cells contributes to glioma neovascularization. Oncol Res. 2015;34:2022-2030.
103. Schichor C, Albrecht V, Korte B, et al. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol. 2012;234:208-219.
114. Dasari VR, Velpula KK, Kaur K, et al. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One. 2010;5:e11813.

115. Velpula KK, Dasari VR, Tsung AJ, et al. Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PLoS One. 2011;6:e18017.

116. Editors PO. Retraction: upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 2020;15:e0231283.

117. Dasari VR, Kaur K, Velpula KK, et al. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 2010;5:e10330.

118. Velpula KK, Dasari VR, Tsung AJ, Dinh DH, Rao JS. Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget. 2011;2:1028-1042.

119. Bajetto A, Pattarozzi A, Corsaro A, et al. Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front Cell Neurosci. 2017;11:312.

120. Ho IA, Toh HC, Ng WH, et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells. 2013;31:146-155.

121. Caplan AI. Mesenchymal stem cells: time to change the name! Stem Cells Translational Med. 2017;6:1445-1451.

122. Yang C, Lei D, Ouyang W, et al. Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Biomed Res Int. 2014;2014:109389.

123. Akimoto K, Kimura K, Nagano M, et al. Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev. 2013;22:1370-1386.

124. Kolosa K, Motani H, Herold-Mende C, et al. Paracrine effects of mesenchymal stem cells induce senescence and differentiation of glioblastoma stem-like cells. Cell Transplant. 2015;24:631-644.

125. Onzi GR, Ledur PF, Hainzenreder LD, et al. Analysis of the safety of mesenchymal stromal mesenchymal stem cells and umbilical cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One. 2010;5:e10330.

126. Edrisie H, Aguzzi A, Adame-Rodriguez C, et al. Mesenchymal stem cells enhance immunoregulatory properties of human glioblastoma through independent cell-cell communication mechanisms. Oncotarget. 2018;9:24766-24777.

127. Vieira de Castro J, Gomes ED, Granja S, et al. Impact of mesenchymal stem cells’ secretome on glioblastoma pathophysiology. J Transl Med. 2017;15:200.

128. Chistiakova IA, Polianskaia GG. Influence of human fetal mesenchymal stem cells on glioma cell proliferation. A consequence of cellular crosstalk. Tsitologiia. 2014;56:800-808.

129. Biancone L, Bruno S, Deregibus MC, et al. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant. 2012;27:3037-3042.

130. Doorn J, Moll G, Le Blanc K, et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 2012;18:101-115.

131. Fierabracci A, Del Fattore A, Luciano R, et al. Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles. Cell Transplant. 2015;24:133-149.

132. Katsuda T, Kosaka N, Takeshita F, Ochiya T. The therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Proteomics. 2013;13:1637-1653.

133. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19:43-51.

134. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373-383.

135. Witwer KW, Van Balkom BW, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8:1609206.

136. Thery C, Witwer KW, Akawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.

137. Corrado C, Raimondo S, Chiesi A, Ciccia F, de Leo G, Alessandro R. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013;14:5338-5366.

138. Gyergy B, Szabo TG, Pasztai M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667-2688.

139. Riazifar M, Pone EJ, Lotvall J, et al. Stem cell extracellular vesicles: extended messages of regeneration. Annu Rev Pharmacol Toxicol. 2017;57:125-154.

140. Hauser P, Wang S, Didenko VV. Apoptotic bodies: selective detection in extracellular vesicles. Methods Mol Biol. 2017;1554:193-200.

141. Huang YC, Lai LC. The potential roles of stem cell-derived extracellular vesicles as a therapeutic tool. Ann Transl Med. 2019;7:693.

142. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14:195-208.

143. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cells. 2010;4:214-222.

144. Del Fattore A, Luciano R, Saracino R, et al. Differential effects of extracellular vesicles secreted by mesenchymal stem cells from different sources on glioblastoma cells. Expert Opin Biol Ther. 2015;15:495-504.

145. Klopp AH, Gupta A, Spaeath E, Andreeff M, Marini F III. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 2011;29:11-19.

146. Ma Z, Cui X, Lu L, et al. Exosomes from glioma cells induce a tumor-like phenotype in mesenchymal stem cells by activating glycolysis. Stem Cell Res Ther. 2019;10:60.

147. Anderson JD, Johansson HJ, Graham CS, et al. Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-KappaB signaling. Stem Cells. 2016;34:601-613.

148. Yuan O, Lin C, Wagner J, et al. Exosomes derived from human primed mesenchymal stem cells induce mitosis and potentiate growth factor secretion. Stem Cells Dev. 2019;28:398-409.

149. Heo JS, Choi Y, Kim HS, et al. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37:115-125.

150. Abreu SC, Antunes MA, Xisto DG, et al. Bone marrow, adipose, and lung tissue-derived murine mesenchymal stromal cells release different mediators and differentially affect airway and lung parenchyma in experimental asthma. Stem Cells Translational Med. 2017;6:1557-1567.

151. Baglio SR, Rooijers K, Koppers-Lalic D, et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res Ther. 2015;6:127.

152. Eirin A, Zhu XY, Puranik AS, et al. Integrated transcriptomic and proteomic analysis of the molecular cargo of extracellular vesicles derived from porcine adipose tissue-derived mesenchymal stem cells. PLoS One. 2017;12:e0174303.
153. Nowakowski A, Bell GW, et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 2014;15:762-774.

154. Cuiffo BG, Campagne A, Bell GW, et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 2014;15:762-774.

155. Wang M, Zhao C, Shi H, et al. Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer. 2014;110:1199-1210.

156. Sung SY, Liao CH, Wu HP, et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stress response to prostate cancer. PloS ONE. 2013;8:e71637.

157. Figueroa J, Phillips LM, Shahar T, et al. Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587. Cancer Res. 2017;77:5808-5819.

158. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res. 2011;71:3387-3399.

159. Sharif S, Gahremani MH, Soleimani M. Delivery of exogenous miR-124 to glioblastoma multiform cells by Wharton's jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemoresistance. Stem Cell Rev Rep. 2018;14:236-246.

160. Lang FM, Hossain A, Gumj J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro Oncol. 2018;20:380-390.

161. Lee HK, Finniss S, Cazau S, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346-361.

162. Allahverdi A, Arefian E, Soleimani M, et al. MicroRNA-4731-5p delivered by AD-mesenchymal stem cells induces cell cycle arrest and apoptosis in glioblastoma. J Cell Physiol. 2020;Jan 19.http://doi.org/10.1002/jcp.29472. Online ahead of print.

163. Stark MS, Tom LN, Boyle GM, et al. The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor. Oncotarget. 2016;7:49677-49687.

164. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M. MiR-146b-Sp suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 2010;28:1024-1030.

165. Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013;335:201-204.

166. Orzan F, Pellegratta S, Poliani PL, et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma-stem-like cells. Neuroupathol Appl Neurobiol. 2011;37:381-394.

167. Xu H, Zhao G, Zhang Y, et al. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/beta-catenin signaling pathway by targeting EZH2. Stem Cell Res Ther. 2019;10:381.

168. Deng S, Lai MF, Li YP, Xu CH, Zhang HX, Kuang JG. Human marrow stromal cells secrete microRNA-375-containing exosomes to regulate glioma progression. Cancer Gene Ther. 2020;27:203-215.

169. Kim R, Lee S, Lee J, et al. Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy. BMB Rep. 2018;51:406-411.

170. Zhang X, Zhang X, Hu S, et al. Identification of miRNA-7 by genome-wide analysis as a critical sensor for TRAIL-induced apoptosis in glioblastoma cells. Nucleic Acids Res. 2017;45:5930-5944.

171. Munoz JL, Bliss SA, Greco SJ, Ramkisson SH, Ligon KL, Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucl Acids. 2013;2:e126.
191. Jiang X, Fitch S, Wang C, et al. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery. Proc Natl Acad Sci U S A. 2016;113:13857-13862.

192. Wang X, Gao J, Ouyang X, et al. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. Int J Nanomedicine. 2018;13:5231-5248.

193. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin. 2017;38:754-763.

194. Crivelli B, Chlapanidas T, Perteghella S, et al.; Italian Mesenchymal Stem Cell Group (GISM). Mesenchymal stem/stromal cell extracellular vesicles: from active principle to next generation drug delivery system. J Control Release. 2017;262:104-117.

195. Vakhshiteh F, Atyabi F, Ostad SN. Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy. Int J Nanomedicine. 2019;14:2847-2859.

196. Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO. Delivery of therapeutic proteins via extracellular vesicles: review and potential treatments for Parkinson’s disease, glioma, and schwannoma. Cell Mol Neurobiol. 2016;36:417-427.

197. Chopra N, Dutt Arya B, Jain N, et al. Biophysical characterization and drug delivery potential of exosomes from human Wharton’s jelly-derived mesenchymal stem cells. ACS Omega. 2019;4:13143-13152.

198. Gilligan KE, Dwyer RM. Engineering exosomes for cancer therapy. Int J Mol Sci. 2017;18(6):1122.

199. Ullah M, Qiao Y, Concepcion W, Thakor AS. Stem cell-derived extracellular vesicles: role in oncogenic processes, bioengineering potential, and technical challenges. Stem Cell Res Ther. 2019;10:347.

200. Melzer C, Rehn V, Yang Y, et al. Taxol-loaded MSC-derived exosomes provide a therapeutic vehicle to target metastatic breast cancer and other carcinoma cells. Cancer. 2019;11(6):798.

201. Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32:2003-2014.

How to cite this article: Bajetto A, Thellung S, Dellacasagrande I, Pagano A, Barbieri F, Florio T. Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. STEM CELLS Transl Med. 2020;9:1310–1330. https://doi.org/10.1002/sctm.20-0161